Concepedia

Bronwyn Bosch

BB

Statistics

Publications

6

Citations

172

H-Index

6

Active since

2021

Affiliations

University of the Witwatersrand(Current)

University of Liverpool

Imperial College London

London School of Economics and Political Science

Université de Montpellier

Bronwyn Bosch is an author at University of the Witwatersrand specializing in pharmacotherapy, clinical pharmacology, and weight management.

ORCID

Publications per year

2021–2024

6

Publications

6

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana et al. · Clinical Infectious Diseases · 2022 · 57 citations · Full text

, , +16

Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens

Simiso Sokhela, François Venter, Bronwyn Bosch et al. · Open Forum Infectious Diseases · 2024 · 35 citations · Full text

, , +16

Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial

Toby Pepperrell, François Venter, Kaitlyn McCann et al. · Clinical Infectious Diseases · 2021 · 32 citations · Full text

, , +13

Weight gain stopping/switch rules for antiretroviral clinical trials

François Venter, Simiso Sokhela, Alexandra Calmy et al. · AIDS · 2021 · 21 citations · Full text

, , +12

Risks of metabolic syndrome in the ADVANCE and NAMSAL trials

Tamara Tovar-Sanchez, Mireille Mpoudi-Etame, Charles Kouanfack et al. · Frontiers in Reproductive Health · 2023 · 17 citations · Full text

, , +12

1–5 of 6